Navigation Links
Time to tumor growth helps predict survival benefit of Bevacizumab for patients with metastatic colorectal cancer
Date:5/8/2013

ST. LOUIS, MO May 8, 2013 Certara, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer. These results are now published online in the Journal of Clinical Oncology. A copy of the results can be obtained here, together with a commentary by Michael Maitland, MD, Ph.D., assistant professor of Medicine in the Section of Hematology/Oncology, and associate director, Committee on Clinical Pharmacology and Pharmacogenomics at the University of Chicago Medicine, Chicago, IL.

Researchers estimated several tumor-size response metrics using longitudinal tumor-size models and data from two Phase III clinical trials, which compared bevacizumab with chemotherapy versus chemotherapy alone as first-line therapy for colorectal cancer. Trial participants included 923 Western and 203 Chinese patients. Baseline prognostic factors and the tumor-size metric estimates were assessed in multivariate models to predict overall survival. Multiple simulations of the Phase III studies were used to test the models' predictive capabilities.

Time to tumor growth proved to be the best metric for predicting overall survival. The proposed model worked equally well when predicting overall survival rates for the Western and Chinese patients and as such could be used to support drug development decisions in either population.

Ren Bruno, Ph.D., managing director of Certara's Pharsight Consulting Services Europe, and senior author of the paper, said: "This approach of combining modeling with longitudinal tumor-size data may contribute to improved design and analysis of more informative early-stage clinical studies (Phase Ib, II). It could also enable researchers to select the most promising treatments and reduce the high attrition rate in Phase III oncology studies."

Robert Powell, PharmD, former senior advisor at Roche China, and co-author of the paper, added: "It is important to know whether patients in a new market (e.g., China, India, Brazil) will be similar to patients in the original US or EU New Drug Application (NDA). While pharmaceutical companies usually assume patients from different regions are the same, there is emerging evidence that they might be different with regard to efficacy, safety and dose response. This type of analysis helps better define Chinese colon cancer response relative to Western patients. Roche performed this combined Chinese and US NDA study analysis to learn whether Chinese patients responded similarly to Western patients so they can use this information to plan future trials. Likewise knowing these results will be important to local regulatory agencies such as the China Food and Drug Administration in this case."


'/>"/>

Contact: Lisa Osborne
lisa@ranahealth.com
206-992-5245
Rana Healthcare Solutions LLC
Source:Eurekalert

Related medicine news :

1. Improved Stem Cell Line May Avoid Tumor Risk: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Dental X-Rays May Be Linked to Benign Brain Tumors
4. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
5. Brain Tumor Vaccine Shows Promise in Early Trial
6. Kidney Cancer Patients Fare Better With Tumor Removal Only
7. IBN discovers human neural stem cells with tumor targeting ability
8. Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor
9. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
10. New surgical technique for removing inoperable tumors of the abdomen
11. Combination of 2 drugs reverses liver tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
Breaking Medicine Technology: